company background image
IDX

Integral DiagnosticsASX:IDX Stock Report

Market Cap

AU$946.8m

7D

0.6%

1Y

17.9%

Updated

22 Oct, 2021

Data

Company Financials +
IDX fundamental analysis
Snowflake Score
Valuation2/6
Future Growth3/6
Past Performance4/6
Financial Health3/6
Dividends3/6

IDX Overview

Integral Diagnostics Limited, a healthcare services company, provides diagnostic imaging services to general practitioners, medical specialists, and allied health professionals and their patients in Australia and New Zealand.

Price History & Performance

Summary of all time highs, changes and price drops for Integral Diagnostics
Historical stock prices
Current Share PriceAU$4.80
52 Week HighAU$4.00
52 Week LowAU$5.55
Beta0.96
1 Month Change1.48%
3 Month Change-10.95%
1 Year Change17.94%
3 Year Change81.82%
5 Year Change198.14%
Change since IPO162.30%

Recent News & Updates

Sep 13
Does Integral Diagnostics (ASX:IDX) Deserve A Spot On Your Watchlist?

Does Integral Diagnostics (ASX:IDX) Deserve A Spot On Your Watchlist?

Like a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...

Jun 04
An Intrinsic Calculation For Integral Diagnostics Limited (ASX:IDX) Suggests It's 22% Undervalued

An Intrinsic Calculation For Integral Diagnostics Limited (ASX:IDX) Suggests It's 22% Undervalued

How far off is Integral Diagnostics Limited ( ASX:IDX ) from its intrinsic value? Using the most recent financial data...

May 14
Should You Be Adding Integral Diagnostics (ASX:IDX) To Your Watchlist Today?

Should You Be Adding Integral Diagnostics (ASX:IDX) To Your Watchlist Today?

It's only natural that many investors, especially those who are new to the game, prefer to buy shares in 'sexy' stocks...

May 03
Is Integral Diagnostics Limited (ASX:IDX) A Smart Choice For Dividend Investors?

Is Integral Diagnostics Limited (ASX:IDX) A Smart Choice For Dividend Investors?

Today we'll take a closer look at Integral Diagnostics Limited ( ASX:IDX ) from a dividend investor's perspective...

Shareholder Returns

IDXAU HealthcareAU Market
7D0.6%1.1%0.7%
1Y17.9%13.1%21.4%

Return vs Industry: IDX exceeded the Australian Healthcare industry which returned 13.1% over the past year.

Return vs Market: IDX underperformed the Australian Market which returned 21.4% over the past year.

Price Volatility

Is IDX's price volatile compared to industry and market?
IDX volatility
IDX Beta0.96
Industry Beta0.60
Market Beta1

Stable Share Price: IDX is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: IDX's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
20081,524Ian Kadishhttps://www.integraldiagnostics.com.au

Integral Diagnostics Limited, a healthcare services company, provides diagnostic imaging services to general practitioners, medical specialists, and allied health professionals and their patients in Australia and New Zealand. The company provides its services through 67 radiology clinics. Integral Diagnostics Limited was incorporated in 2008 and is headquartered in Melbourne, Australia.

Integral Diagnostics Fundamentals Summary


Earnings & Revenue

Key profitability statistics from the latest earnings report
IDX income statement (TTM)
RevenueAU$350.70m
Cost of RevenueAU$221.45m
Gross ProfitAU$129.25m
ExpensesAU$97.98m
EarningsAU$31.27m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)0.16
Gross Margin36.85%
Net Profit Margin8.92%
Debt/Equity Ratio73.8%

How did IDX perform over the long term?

See historical performance and comparison

Dividends

2.6%

Current Dividend Yield

79%

Payout Ratio

Valuation

Is Integral Diagnostics undervalued compared to its fair value and its price relative to the market?

40.5%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: IDX (A$4.8) is trading below our estimate of fair value (A$8.07)

Significantly Below Fair Value: IDX is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: IDX is poor value based on its PE Ratio (30.7x) compared to the Australian Healthcare industry average (24.7x).

PE vs Market: IDX is poor value based on its PE Ratio (30.7x) compared to the Australian market (19.8x).


Price to Earnings Growth Ratio

PEG Ratio: IDX is poor value based on its PEG Ratio (2.1x)


Price to Book Ratio

PB vs Industry: IDX is overvalued based on its PB Ratio (3.8x) compared to the AU Healthcare industry average (2.2x).


Future Growth

How is Integral Diagnostics forecast to perform in the next 1 to 3 years based on estimates from 11 analysts?

14.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: IDX's forecast earnings growth (14.7% per year) is above the savings rate (1.9%).

Earnings vs Market: IDX's earnings (14.7% per year) are forecast to grow faster than the Australian market (11.5% per year).

High Growth Earnings: IDX's earnings are forecast to grow, but not significantly.

Revenue vs Market: IDX's revenue (8.3% per year) is forecast to grow faster than the Australian market (5.3% per year).

High Growth Revenue: IDX's revenue (8.3% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: IDX's Return on Equity is forecast to be low in 3 years time (15.8%).


Past Performance

How has Integral Diagnostics performed over the past 5 years?

18.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: IDX has high quality earnings.

Growing Profit Margin: IDX's current net profit margins (8.9%) are higher than last year (8.4%).


Past Earnings Growth Analysis

Earnings Trend: IDX's earnings have grown by 18.4% per year over the past 5 years.

Accelerating Growth: IDX's earnings growth over the past year (35.8%) exceeds its 5-year average (18.4% per year).

Earnings vs Industry: IDX earnings growth over the past year (35.8%) underperformed the Healthcare industry 61.3%.


Return on Equity

High ROE: IDX's Return on Equity (12.3%) is considered low.


Financial Health

How is Integral Diagnostics's financial position?


Financial Position Analysis

Short Term Liabilities: IDX's short term assets (A$82.3M) exceed its short term liabilities (A$77.9M).

Long Term Liabilities: IDX's short term assets (A$82.3M) do not cover its long term liabilities (A$322.3M).


Debt to Equity History and Analysis

Debt Level: IDX's debt to equity ratio (73.8%) is considered high.

Reducing Debt: IDX's debt to equity ratio has increased from 48.6% to 73.8% over the past 5 years.

Debt Coverage: IDX's debt is well covered by operating cash flow (37%).

Interest Coverage: IDX's interest payments on its debt are well covered by EBIT (5.7x coverage).


Balance Sheet


Dividend

What is Integral Diagnostics's current dividend yield, its reliability and sustainability?

2.60%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: IDX's dividend (2.6%) is higher than the bottom 25% of dividend payers in the Australian market (2.27%).

High Dividend: IDX's dividend (2.6%) is low compared to the top 25% of dividend payers in the Australian market (5.31%).


Stability and Growth of Payments

Stable Dividend: IDX has been paying a dividend for less than 10 years and during this time payments have been volatile.

Growing Dividend: IDX's dividend payments have increased, but the company has only paid a dividend for 5 years.


Current Payout to Shareholders

Dividend Coverage: At its current payout ratio (79.1%), IDX's payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: IDX's dividends in 3 years are forecast to be covered by earnings (61.8% payout ratio).


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.9yrs

Average management tenure


CEO

Ian Kadish (58 yo)

4.42yrs

Tenure

AU$1,547,721

Compensation

Dr. Ian Kadish, MBBCh, MBA, has been the Chief Executive Officer, Managing Director and Director at Integral Diagnostics Limited since May 22, 2017. Dr. Kadish serves as Independent Non-Executive Director...


CEO Compensation Analysis

Compensation vs Market: Ian's total compensation ($USD1.16M) is about average for companies of similar size in the Australian market ($USD973.44K).

Compensation vs Earnings: Ian's compensation has increased by more than 20% in the past year.


Leadership Team

Experienced Management: IDX's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.


Board Members

Experienced Board: IDX's board of directors are considered experienced (5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Integral Diagnostics Limited's employee growth, exchange listings and data sources


Key Information

  • Name: Integral Diagnostics Limited
  • Ticker: IDX
  • Exchange: ASX
  • Founded: 2008
  • Industry: Health Care Services
  • Sector: Healthcare
  • Market Cap: AU$946.793m
  • Shares outstanding: 200.17m
  • Website: https://www.integraldiagnostics.com.au

Number of Employees


Location

  • Integral Diagnostics Limited
  • 45 William Street
  • Suite 9.02
  • Melbourne
  • Victoria
  • 3000
  • Australia

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/22 07:05
End of Day Share Price2021/10/22 00:00
Earnings2021/06/30
Annual Earnings2021/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.